2. Search Result
Search Result
Results for "

Fusion+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

9

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0052
    Enfuvirtide
    4 Publications Verification

    T20; DP178

    		 HIV Infection
    Enfuvirtide (T20;DP178) is an anti-HIV-1 fusion inhibitor peptide.
    Enfuvirtide
  • HY-16727
    Presatovir
    5+ Cited Publications

    GS-5806

    		 RSV Infection
    Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC50 value of 0.43 nM .
    Presatovir
  • HY-11097
    TMC353121
    Maximum Cited Publications
    8 Publications Verification

    		 RSV Infection
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
    TMC353121
  • HY-P0052A
    Enfuvirtide acetate
    4 Publications Verification

    T20 acetate; DP178 acetate

    		 HIV Infection
    Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide.
    Enfuvirtide acetate
  • HY-121219
    (-)-Lupinine

    		Bacterial Infection
    (-)-Lupinine is an alkaloid and membrane fusion inhibitor. (-)-Lupinine does not affect the synthesis of proinflammatory cytokines during the host response to Serratia proteamaculans infection. (-)-Lupinine can enhance the expression of the bacterial surface protein OmpX. (-)-Lupinine can be used for research on bacterial infections .
    (-)-Lupinine
  • HY-12994
    VP-14637

    MDT-637

    		 RSV Infection
    MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC50 of 1.42 ng/mL.
    VP-14637
  • HY-W048674
    Fmoc-Ser(Ac)-OH

    Fmoc-O-acetyl-L-serine

    		 Amino Acid Derivatives Infection
    Fmoc-Ser(Ac)-OH (Fmoc-O-acetyl-L-serine) is a Serine derivative. Fmoc-Ser(Ac)-OH can be used for the preparation of broad-spectrum coronavirus membrane fusion inhibitor .
    Fmoc-Ser(Ac)-OH
  • HY-122907
    JNJ4796

    		Influenza Virus Infection
    JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) .
    JNJ4796
  • HY-P2200
    Siamycin I

    BMY-29304

    		 HIV Antibiotic Infection Inflammation/Immunology
    Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .
    Siamycin I
  • HY-P11012
    EK1

    		SARS-CoV Infection
    EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .
    EK1
  • HY-P35433
    Tifuvirtide

    T-1249

    		 HIV Inflammation/Immunology
    Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .
    Tifuvirtide
  • HY-P10517
    Sifuvirtide

    SFT

    		 HIV Infection
    Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .
    Sifuvirtide
  • HY-168616
    CL-A3-7

    		RSV IGF-1R Infection
    CL-A3-7 is a virus-cell fusion inhibitor targeting the RSV F protein. It exerts its effect by blocking the interaction between the virus and the host IGF1R, effectively inhibiting infections of both wild-type RSV and the K394R variant. It is applicable to anti-RSV drug development and resistance-related research .
    CL-A3-7
  • HY-23193
    BMS-199945

    		Influenza Virus Infection
    BMS-199945 is a influenza virus fusion inhibitor with the IC50 values of 0.57 μM and approximately 1 μM aganist influenza A/WSN/33 virus-induced hemolysis of chicken RBC and in the trypsin protection assay, respectively .
    BMS-199945
  • HY-119375
    Syncytial Virus Inhibitor-1

    		Bacterial Infection
    Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively .
    Syncytial Virus Inhibitor-1
  • HY-P10517A
    Sifuvirtide acetate

    SFT acetate

    		 HIV Infection
    Sifuvirtide (SFT) acetate is a potent HIV fusion inhibitor. Sifuvirtide acetate inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide acetate can be used in the research of anti-HIV drugs .
    Sifuvirtide acetate
  • HY-149368
    SARS-CoV-2-IN-51

    		SARS-CoV Infection
    SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC50s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state .
    SARS-CoV-2-IN-51
  • HY-P3492
    SARS-CoV-2-IN-34

    		SARS-CoV Infection
    SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .
    SARS-CoV-2-IN-34
  • HY-175808
    VF-57a

    		Influenza Virus Infection
    VF-57a (Compound 23) is an Influenza A virus (IAV) fusion inhibitor. VF-57 has potent antiviral activities against authentic A/H1N1 virus with EC50s of 0.92 and 0.31 μM for the A/H1N1 PR8 and A/H1N1 Virg09 strains, respectively. VF-57 significantly inhibits HA-mediated cell entry of A/H1N1- and A/H5N1-pseudoviruses, prevents the HA refolding at pH 5.2. VF-57a can be used for IAV infections research .
    VF-57a
  • HY-175829
    SARS-CoV-2-IN-119

    		SARS-CoV Infection
    SARS-CoV-2-IN-119 (Compound A28) is a SARS-CoV-2 fusion inhibitor. SARS-CoV-2-IN-119 strongly inhibits Omicron entry with an EC50s of 1.95  and 1.08 μM for pOmicron (BA.2.86.1) and wild Omicron. SARS-CoV-2-IN-119 also has antiviral activities against wild SARS-CoV-2 and other variants, such as pseudotyped Delta SARS-CoV-2, pOmicron (BA.4) and (KP.3). SARS-CoV-2-IN-119 directly interferes with Omicron S2-mediated viral membrane fusion to block Omicron virus into host cells. SARS-CoV-2-IN-119 can be used for COVID-19 research .
    SARS-CoV-2-IN-119

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: